International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients

As of yet, there has been only one clinical trial focused purely on CMML as its own condition.
However, there’s good news.

New Research

Two European societies have recently published joint recommendations for CMML specifically. Their evaluations are outlined by the European Hematology Association in their journal, HemaSphere. The goal was to decrease the knowledge gap for the condition.
European and US experts worked on the article, aiming to provide a more specialized analysis for CMML patients regarding diagnosis and treatment. This evaluation is especially important because not only is the condition incredibly unique, each individual patient experiences it differently. This means each individual patient requires a special form of treatment.

The end goal of the evaluation was to establish recommendations for clinical practice which were specific to CMML. The experts organized their results into three components: diagnosis, prognosis, and treatment. Here are some of the highlights:

– Diagnosis: Use blood tests, flow cytometry, bone marrow tests, and molecular genetic tests.

– Prognosis: Patient factors and disease factors need to be considered when evaluating and predicting outcomes.

– Treatment: Will vary depending on the patients. May include- watchful waiting for some patients and stem cell transplants for others.

Looking Forward

Not only did this evaluation result in more specific CMML recommendations, it established an international collaborative network which should help us continue to expand our knowledge of this disease in the future.

Even better than this evaluation, is that these experts know their opinion isn’t enough. They emphasize the fact that we need to include more CMML patients (at all stages of the condition) in clinical trials. Yes, their evaluation is progress, but we still need more hard data on this disease.

The moral of the story is- CMML is a unique diagnosis. It can’t be treated like cancers which are “similar”. In order to get the best outcome for patients, we need to evaluate the characteristics of their specific disease. Ultimately, a standardized approach for the condition should help improve outcomes for CMML patients.

You can read more about this investigation here.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Close Menu